ReviewCurrent rheumatology reports2020
New Criteria for Lupus.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus.JAAD case reports · 2026Article
- Advances and pitfalls in anti-double-stranded DNA autoantibody detection and interpretation.World journal of biological chemistry · 2026Review
- From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists.The Journal of clinical and aesthetic dermatology · 2025Review
- Philosophical and distinct SLE epitomes: dogmas in conflict with evidences and an intellectual dissonance between established pathophysiological models.Frontiers in immunology · 2025Review
- Serum 25-Hydroxyvitamin D Levels and Disease Activity in Patients with Systemic Lupus Erythematosus: An Exploratory Study in Western Mexico.Diseases (Basel, Switzerland) · 2024Article
- Castleman's disease in the rheumatological practice.Zeitschrift fur Rheumatologie · 2024Review
- Discrepant anti-dsDNA testing between EliA andLupus science & medicine · 2024Article
- [Castleman's disease in the rheumatological practice].Zeitschrift fur Rheumatologie · 2024Review
- Drug-Induced Lupus Following mRNA COVID-19 Vaccination and Monoclonal Antibody Infusion for Treatment of COVID-19 Infection.Kansas journal of medicine · 2024Article
- Childhood-onset systemic lupus erythematosus in the first year of life with joint involvement: A case report and mini-review.Journal of family medicine and primary care · 2022Article
- A Study of Clinical and Serological Correlation of Positive Direct Antiglobulin Test in Blood Bank at a Tertiary Care Center.Journal of laboratory physicians · 2022Article
- Anti-tumour necrosis factor-α-induced lupus in a patient receiving infliximab for sarcoidosis.Respirology case reports · 2022Article
- The Past, Present, and Future in Antinuclear Antibodies (ANA).Diagnostics (Basel, Switzerland) · 2022Review
- SLE classification criteria: Science-based icons or algorithmic distractions - an intellectually demanding dilemma.Frontiers in immunology · 2022Article
- Article
- Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters.Frontiers in immunology · 2022Article
- Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.Journal of translational autoimmunity · 2022Article
- Article
- Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease.Journal of clinical medicine · 2021Article
- Acquired White Oral Lesions with Specific Patterns: Oral Lichen Planus and Lupus Erythematosus.Dermatology practical & conceptual · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewClassification criteria define the patient population for clinical trials and translational studies, but also influence current understanding of the disease. This review attempts to delineate the development from the American College of Rheumatology (ACR) 1982 to the European League Against Rheumatism (EULAR)/ACR 2019 classification criteria for systemic lupus erythematosus (SLE). RECENT
findingsThe new EULAR/ACR classification criteria use antinuclear antibodies (ANA) as an entry criterion. (Non-infectious) fever is the one new criterion. All criteria items now have individual weights (from 2 to 10) and are structured in domains, within which only the highest item is counted. There is one common attribution rule, counting criteria only if there is no more likely alternative explanation. Ten points are sufficient for classification. The new criteria have reached a sensitivity of 96.1% and a specificity of 93.4%. The new EULAR/ACR 2019 classification criteria for SLE build on the previous criteria sets, adding fever only as a new criteria item. The new structure is reflective of the current diagnostic approach and has led to improved statistical performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.